Zentalis Pharmaceuticals Reaches Analyst Target Price
September 16, 2021 at 10:28 AM EDT
In recent trading, shares of Zentalis Pharmaceuticals Inc (ZNTL) have crossed above the average analyst 12-month target price of $73.00, changing hands for $73.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..